(Q37801269)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Human immunodeficiency virus-1 vaccine design: where do we go now? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ronald J Jackson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Ian A Ramshaw

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Charani Ranasinghe

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

19 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

Immunology & Cell Biology

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

367-374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

The role of antibodies in HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Evolutionary and immunological implications of contemporary HIV-1 variation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

21 January 2018

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

The search for protection against HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

New hope for an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

HIV preferentially infects HIV-specific CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Immune mechanisms of HIV control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

T-cell exhaustion: characteristics, causes and conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

HIV-1 prophylactic vaccine trials in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

The immune response during acute HIV-1 infection: clues for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

T-cell quality in memory and protection: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Avidity of CD8 T cells sharpens immunodominance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

A single peripheral CD8+ T cell can give rise to progeny expressing type 1 and/or type 2 cytokine genes and can retain its multipotentiality through many cell divisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Functional implications of T cell receptor diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

HIV vaccine design: insights from live attenuated SIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Protective immunity induced by live attenuated simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Immunology and the elusive AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

inferred from DOI database lookup

7 January 2021

based on heuristic

Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

inferred from DOI database lookup

7 January 2021

based on heuristic

RANTES potentiates antigen-specific mucosal immune responses

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.118

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ICB.2010.118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956986%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference